256 results about "Viral antibody" patented technology

The invention relates to the technical field of biology, particularly the field of viral antibody detection. A kit for detecting the antibody against Peste des petits ruminants virus b-ELISA comprises the following ingredients which are arranged respectively: Peste des petits ruminants nucleoprotein antigen, Peste des petits ruminants monoclonal antibody, diluent, strong positive serum, weak positive serum, negative serum, HRP sheep anti-mouse secondary antibody, 20 times the concentration of washing liquid, substrate liquid, stopping solution and enzyme-linked immunosorbent plate. The optimum proportion of each ingredient in the kit is determined by experiments. The kit can be used for rapid diagnosis and detection of animal Peste des petits ruminants virus antibody, especially for the antibody detection of a lot of samples in the epidemiological survey of Peste des petits ruminants. The detection method of Peste des petits ruminants virus b-ELISA has different detection principle and experiment operating procedures and the like from those of a c-ELISA detection method in a BIRAD laboratory. The Peste des petits ruminants nucleoprotein antigen and Peste des petits ruminants monoclonal antibody in the kit are self-developed. The detection sensitivity, singularity and other indexes of the kit are the same with those of the c-ELISA detection method in the internationally recognized BIRAD laboratory.

The invention discloses a hybridoma cell line of a monoclonal antibody against African swine fever virus and the secreted monoclonal antibody thereof. The preparation method of the invention comprises the following steps: preparing a recombined P30 soluble antigen by prokaryotic expression; immunizing a BALB/c mouse; and finally fusing, screening and cloning by a hybridoma technology to obtain the hybridoma cell line which can stably secrete the monoclonal antibody against African swine fever virus P30 protein. The invention further discloses a method for preparing the monoclonal antibody with the cell line, an antibody purification method and a labeling method for horseradish peroxidase of the antibody. The monoclonal antibody can be used in detecting the African swine fever viral antibody in pig serum.

The invention discloses a Korean novel duck hepatitis viral antibody ELISA (Enzyme-Linked Immunosorbent Assay) detection kit. The detection kit contains an ELISA board coated by Korean novel duck hepatitis VP1 (Phenotypic Variance1) recombination protein, a sample diluent, concentrated washing liquid, an enzyme conjugate working solution, a chromogenic reagent (A), a chromogenic reagent (B), a stopping solution, a positive contrast solution and a negative contrast solution. The VP1 recombination protein is obtained by using the following method: using Korean novel duck hepatitis viruses as a material, augmenting and cloning the VP1 gene through an RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction) method to obtain recombinant expression plasmid pMD (physical medium dependent)-VP1; then, directionally inserting to an expression vector pET-32a (+) and screening to obtain recombinant expression plasmid pET-32a(+)-VP1; and inducing, expressing and purifying by ITPG (Isopropyl beta-D-Thiogalactopyranoside) to obtain VP1 recombination protein. The detection kit is used for detecting the Korean novel duck hepatitis and has strong specificity, high sensitivity, simplicity of operation, easiness of popularization and application in a large-area range and wide market prospects.

A process for selectively immobilizing viral glycoproteins on lectin-coated surfaces for use in solid phase immunoassays is disclosed. This method does not require that the virus or antigen be purified prior to immobilization. This method provides an inexpensive and effective immunoassay method to screen fluids for the presence of viral antibodies.

It is intended to provide a drug which is efficacious in treating a prion disease and has a high safety. A remedy for a prion disease which contains a mesenchymal stem cell as the active ingredient and a method of producing the same. A remedy for a prion disease which contains a mesenchymal stem cell, in particular, a mesenchymal stem cell having an anti-prion antibody gene transferred thereinto as the active ingredient and a method of producing the same. These remedies can not only prevent the progress of a prion disease but also contribute to the recovery of nerve dysfunction caused by the disease.

The invention discloses infective clone for porcine circovirus type 1 and rescued virus and application thereof. Two genomes of the porcine circovirus type 1 are connected in cis and inserted into a vector to construct and obtain an infective molecular clone. A Sal I enzyme cutting site as a molecular target is inserted in the infective molecular clone. A rescued recombinant virus (PCV1/G strains) carries a molecular marker, and the preservation number of the rescued recombinant virus is CGMCC NO.2658. An antigen of the recombinant virus is only reacted with a univalent specific antibody of PCV1/Cap protein, but has no cross with an antibody against PCV2/Cap protein. The recombinant virus and a parental virus are identified by combination of PCR and RFLP. The virus strain cultured in vitro has stable propagation property and high virus titer, and the rescued virus strain can be used for detecting the antibody of the virus. The invention lays a foundation for research such as genesis and evolution, genetic variation rule, molecular differential diagnosis, and the like for porcine circovirus in future.

The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.

This invention relates to a detection mode of SARS virus antibody and a preparing method of the box for rapid diagnosis reagent. The checking method includes that (1) putting antihuman Ig antibody marked by colloidal gold in the carrier, and coating detecting thread made of variant antigen of SARS coronavirus and controlling thread made of antipest IgG antibody in the detecting carrier connecting with the marked one. (2) putting human serum in the marked carrier. The box for rapid diagnosis reagent includes checkerboard marked by variant antibody of SARS coronavirus, which comprises water-absorbing layer of adding-kind edge, detecting layer and water-absorbing layer of water-uptake edge. There is antihuman Ig antibody layer between detecting layer and water-absorbing layer of water-uptake edge, and in the detecting layer there is detecting thread made of variant antigen of SARS coronavirus and controlling thread made of antipest IgG antibody coating.

The embodiment of the invention provides a biosensor, a preparation method, a virus detection system and method. The method comprises the following steps: modifying a virus antigen or a virus antibodyor a nucleic acid probe for detecting viruses on a biosensor through bridging molecules capable of connecting various biomacromolecules, inputting a to-be-detected sample into the biosensor, and analyzing current signals before and after reaction, so as to detect whether viruses exist in the to-be-detected sample or not. The bridging molecule of the biosensor provided by the embodiment of the invention can be connected with various biomacromolecules, so that different viruses can be detected.

The invention provides a polypeptide chip, which comprises a substrate and n polypeptides distributed on the substrate in an array, each polypeptide sequence has 10-20 amino acids, a group consistingof sequences of first to nth polypeptides covers at least 95% of a viral protein sequence, the adjacent polypeptides have an overlap of 3-8 amino acids, and n is 810-1370. According to the method, proteomics and system biology strategies are adopted, all coded protein sequences of COVID-19 are extracted from NCBI data, an SARS-CoV-2 virus proteome polypeptide chip is designed and prepared, and panoramic scanning of all SARS-CoV-2 virus antibodies in blood of a novel pneumonia virus infected patient is achieved.

The invention relates to a colloidal gold immunochromatography test strip for simultaneously detecting viral antigens and antibodies. The test strip comprises a first glue strip and a second glue strip which are arranged in parallel, wherein the first glue strip comprises a first sample pad, a first conjugate pad, a first nitrocellulose membrane and first absorbent paper, which are sequentially lapped with one another, the first conjugate pad is coated with colloidal gold marked by the viral antigens, the first nitrocellulose membrane is coated with viral antibodies and antibodies, the viral antibodies are taken as a first detection line, and the antibodies are used for resisting the viral antigens on the colloidal gold and are taken as a quality control line; the second glue strip comprises a second sample pad, a second conjugate pad, a second nitrocellulose membrane and second absorbent paper, which are sequentially lapped with one another, the second conjugate pad is coated with the colloidal gold marked by the viral antigens, the second nitrocellulose membrane is coated with anti-human IgG antibodies and anti-human IgM antibodies, the anti-human IgG antibodies are taken as a second detection line, and the anti-human IgM antibodies are taken as a third detection line. The colloidal gold immunochromatography test strip can be used for simultaneously detecting the viral antigens as well as the IgG antibodies and IgM antibodies of the viral antigens.

The invention provides a novel viral vaccine for treating a non-small cell lung cancer and a preparation method thereof. The preparation method of the viral vaccine comprises the first step of constructing a carrier of an MVA virus and the second step of obtaining specificity presenting MAGE-3 antigen DC cells. According to the viral vaccine prepared through the method, the biological stability is high, adverse effects on human bodies are not produced, and pathogenic dangers do not exist; a virus antibody can obtain a large number of viral particles with high purity easily; MAGE-A3 expressed by the viral vaccine has better immunogenicity, more epitopes are achieved, and drug resistance is not prone to being caused; the viral load needed in inoculation of the viral vaccine is smaller than other viruses.

A method for treating a virus-containing sample, characterized by treatment of a virus-containing sample with a treatment solution containing (1) an anionic surfactant and (2) an amphoteric surfactant, nonionic surfactant or protein denaturant; a virus assay method using said treating method; a method for treating a virus-containing sample, characterized by treatment of a virus-containing sample with a treatment solution containing (1) a chaotropic ion and (2) an acidifying agent; a virus assay method using said treating method; a virus assay method, characterized in that a virus antigen and a virus antibody are measured based on their binding to their probe in the presence of a surfactant with an alkyl group of 10 or more carbon atoms and a secondary, tertiary or quaternary amine, or a nonionic surfactant, or of both of them; and a monoclonal antibody and a hybridoma producing the same for carrying out said method.

The invention relates to an O-type foot-and-mouth disease virus antibody chemiluminescence detection kit. The kit includes an polystyrene board coated by antigen, a monoclonal antibody, a standard substance, a luminescence substrate solution A and a luminescence substrate solution B. The polystyrene board coated by antigen is an opaque polystyrene plate coated by an O-type foot-and-mouth disease virus RE2 recombinant protein; the monoclonal antibody is a horseradish peroxidase labeled O-type foot-and-mouth virus monoclonal antibody; the luminescence substrate solution A comprises a Lumino, hydroxycoumarin, gallic acid, a Tris-Hcl buffer and water; the standard substance is foot-and-mouth virus O-type antibody respectively diluted buy a calibration diluent, wherein the dilution is 0NU / mL, 2NU / mL, 5NU / mL, 10NU / mL, 30NU / mL and 60NU/ mL respectively. The kit of the invention can be used for detecting O-type foot-and-mouth disease virus antibody, has the advantages of high sensitivity and wide detection range, and realizes the quantitative detection of foot-and-mouth disease antibody.

The invention discloses SARS-CoV-2 antigen polypeptides and application thereof. The invention relates to four SARS-CoV-2 polypeptide antigens and application thereof. The amino acid sequences of thefour SARS-CoV-2 polypeptide antigens are SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 or derivative sequences thereof. The epitopes screened out in the invention can be used for detecting anSARS-CoV-2 virus antibody, are high in specificity and accuracy, have an application value in clinical diagnosis, and play a positive and effective role in preventing and controlling SARS-CoV-2 virusinfection.

The invention relates to an ELISA (enzyme linked immunosorbent assay) antibody detection kit for an O type foot-and-mouth disease virus and a detection method adopting the ELISA antibody detection kit. The kit comprises components as follows: (1) a recombinant RE2 protein antigen coated Elisa plate, (2) a horseradish peroxidase marked monoclonal antibody, (3) negative control, (4) positive control, (5) a washing solution, (6) a sample diluent, (7) a developing solution A and a developing solution B and (8) a stop solution. The detection kit combines a monoclonal antibody technology and a solid-phase ELISA detection technology, has the characteristics of rapidness, accuracy, stability and the like, and can be used for immune effect monitoring of a livestock farm as well as rapid and batch antibody detection of epidemic diseases of an inspection and quarantine department, an export port and the like.

The invention discloses a high-stability novel coronavirus spike protein, a related biological material, application of the related biological material, detection test paper and a detection kit, relates to the field of biotechnology and biomedicine. The bottleneck of the industry is broken through through internal crosslinking modification on the optimal antigen spike protein, namely S protein, onthe surface of novel coronavirus, The high-stability full-length S protein trimer is obtained through expression and purification in mammals, all antigen epitopes of the new coronavirus surface spikeprotein are reserved to the maximum extent, the stable S protein serves as an antigen to capture a new coronavirus antibody in a patient sample, and a novel coronavirus antibody instant detection kitwith high accuracy, high sensitivity and high stability is produced.

The invention provides a novel severe acute respiratory syndrome coronavirus 2 N proteantigen variant and an application thereof to detection of the novel severe acute respiratory syndrome coronavirus2 antibody, and relates to variants of N protein important epitope polypeptide. The variants reduce the non-specific reaction of the novel severe acute respiratory syndrome coronavirus 2 protein as acapture antigen with other coronavirus antibodies such as SARS and human influenza coronavirus antibodies. The polypeptide has coronavirus N protein epitope peptide activity, and cysteine residues are added to the C end of the polypeptide. Amino acid residue sites of the mutation are selected from: lysine at the 342rd site, lysine at the 347 site, lysine at the 387 site and lysine atthe 388 site are mutated into amino acids with relatively low homology. The sequence of the N protein 340-419 polypeptide is shown as SEQ ID NO 7. The invention further discloses an antigen composition, use and method of the variant.

The invention discloses an ELISA detection kit for a foot-and-mouth disease O-type virus sIgA antibody and an application thereof. The kit comprises a foot-and-mouth disease O-type virus broad spectrum multi-epitope recombinant antigen coated enzyme labeled reaction plate, a 100*concentrated enzyme labeled antibody, an enzyme labeled antibody diluent, a sample diluent, a concentrated cleaning solution, a developing solution, a stop solution, a positive control sample and a negative control sample. The foot-and-mouth disease O-type virus broad spectrum multi-epitope recombinant antigen is composed of main neutral epitopes of Cathay, PanAsia and Burmese 98 three pedigrees of foot-and-mouth disease O-type virus typical strains, so that the sensitivity and specificity of kit detection can be promoted and the kit is suitable for detection of different foot-and-mouth disease O-type virus infections. The kit provided by the invention is suitable for detection of sIgA antibodies in easily infected animal mucosal secretion of pig, cattle and sheep and has a great significance in preventing and controlling the spreading and infection of foot-and-mouth disease O-type virus.

The invention discloses a one-step rapid and efficient viral nucleic acid extraction method. The one-step rapid and efficient viral nucleic acid extraction method comprises the following steps: (1) allowing binding of a virus antibody or receptor to hydroxyl group, carboxyl group, amino group or epoxy group on surface of magnetic microsphere (MNP) so as to form a stable magnetic microsphere-antibody complex (MNP-Ab); (2) uniformly mixing the MNP-Ab with nucleic acid extraction magnetic beads according to a certain proportion so as to obtain a magnetic bead mixture; (3) adding the magnetic beadmixture into a sample so as to allow virus in the sample to be tested with the MNP-Ab so as to obtain enriched virus; (4) causing lysis on the enriched virus by using a lysis solution so as to have nucleic acids released, and allowing combination of the nucleic acids with the nucleic acid extraction magnetic beads in the magnetic bead mixture; and (5) eluting the nucleic acids by using an eluant.The one-step rapid and efficient viral nucleic acid extraction method truly realizes the ''one-step one-tube method'' that immuno-magnetic beads and nucleic acid extraction magnetic beads are contained in the same container, so that neither of the magnetic beads are required to be removed in the process of operation, so that the one-step rapid and efficient viral nucleic acid extraction method iseasy to operate; and moreover, the immuno-magnetic beads are high in specificity and adsorption rate, high in virus recovery rate, and strong in repeatability.